Table 3 Risk of GORD among hormone replacement users: multiple regression
Oestrogen-only users No. of GORD cases OR (95% CI) P | Tibolone users No. of GORD cases OR (95% CI) P | Combined HRT users No. of GORD cases OR (95% CI) P | Progestogen users No. of GORD cases OR (95% CI) P | |
|---|---|---|---|---|
GORD | ||||
Hormone | 144 | 21 | 137 | 56 |
Non-hormone | 572 | 572 | 572 | 572 |
OR (95% CI) p | 1.49 (1.18–1.89) 0.001 | 0.79 (0.45–1.4) 0.419 | 1.09 (0.87–1.37) 0.445 | 1.29 (0.90–1.84) 0.170 |
NSAIDs <30d | ||||
Hormone | 23 | 3 | 22 | 12 |
Non-hormone | 99 | 99 | 99 | 99 |
OR (95% CI) p | 1.52 (1.09–2.12) 0.014 | 1.08 (0.48–2.48) 0.848 | 1.25 (0.92–1.71) 0.150 | 1.09 (0.68–1.74) 0.718 |
NSAIDs ≥30d | ||||
Hormone | 75 | 14 | 62 | 21 |
Non-hormone | 233 | 233 | 233 | 233 |
OR (95% CI) p | 2.06 (1.59–2.66) < 0.001 | 3.42 (1.22–9.64) 0.020 | 1.97 (1.56–2.50) < 0.000 | 1.14 (0.77–1.68) 0.520 |
Calcium <30d | ||||
Hormone | 1 | 0 | 0 | 0 |
Non-hormone | 10 | 10 | 10 | 10 |
OR (95% CI) p | 0.56 (0.13–2.41) 0.439 | 1.58 (0.31–8.02) 0.582 | 0.49 (0.11–2.06) 0.325 | 4.14 (1.40–12.27) 0.010 |
Calcium ≥30d | ||||
Hormone | 11 | 2 | 11 | 0 |
Non-hormone | 37 | 37 | 37 | 37 |
OR (95% CI) p | 2.15 (1.26–3.66) 0.005 | 1.88 (0.53–6.72) 0.330 | 1.99 (1.18–3.36) 0.010 | 1.64 (0.523–5.07) 0.393 |
Bisphosphonate <30d | ||||
Hormone | 0 | 0 | 1 | 0 |
Non-hormone | 3 | 3 | 3 | 3 |
OR (95% CI) p | 0.56 (0.06–4.80) 0.592 | - (−) 0.999 | 1.11 (0.29–4.26) 0.886 | - (−) 0.999 |
Bisphosphonate ≥30d | ||||
Hormone | 6 | 0 | 4 | 0 |
Non-hormone | 12 | 12 | 12 | 12 |
OR (95% CI) p | 0.93 (0.43–2.04) 0.865 | 0.84 (0.15–4.75) 0.845 | 0.69 (0.27–1.79) 0.445 | 0.75 (0.13–4.27) 0.744 |